Top Growth Companies With High Insider Ownership December 2024
Reviewed by Simply Wall St
As global markets continue to reach record highs, with indices like the Dow Jones Industrial Average and S&P 500 Index hitting new peaks, investors are navigating a landscape influenced by geopolitical developments and domestic policy shifts. In this context of robust market performance and evolving economic conditions, identifying growth companies with high insider ownership can be a strategic approach for those seeking to align their investments with management interests and potentially capitalize on long-term value creation.
Top 10 Growth Companies With High Insider Ownership
Name | Insider Ownership | Earnings Growth |
Seojin SystemLtd (KOSDAQ:A178320) | 30.9% | 39.9% |
Kirloskar Pneumatic (BSE:505283) | 30.3% | 26.3% |
SKS Technologies Group (ASX:SKS) | 32.4% | 24.8% |
Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.3% |
Laopu Gold (SEHK:6181) | 36.4% | 34.2% |
Plenti Group (ASX:PLT) | 12.8% | 120.1% |
Fulin Precision (SZSE:300432) | 13.6% | 66.7% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 110.9% |
Brightstar Resources (ASX:BTR) | 16.2% | 84.6% |
Findi (ASX:FND) | 34.8% | 112.9% |
We'll examine a selection from our screener results.
Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a company engaged in the research, development, and production of biopharmaceutical products with a market cap of CN¥18.34 billion.
Operations: The company generates revenue of CN¥488.45 million from its pharmaceuticals segment.
Insider Ownership: 29.4%
Earnings Growth Forecast: 125.6% p.a.
Suzhou Zelgen Biopharmaceuticals has demonstrated significant revenue growth, increasing from CNY 282.1 million to CNY 384.12 million over the past year, while also reducing its net loss to CNY 97.9 million. The company is trading at a substantial discount to its estimated fair value and is expected to achieve profitability within three years, with forecasted annual earnings growth of 125.59%. Revenue growth is projected at a robust rate of 59.6% annually, outpacing the market average in China.
- Click here to discover the nuances of Suzhou Zelgen BiopharmaceuticalsLtd with our detailed analytical future growth report.
- Upon reviewing our latest valuation report, Suzhou Zelgen BiopharmaceuticalsLtd's share price might be too optimistic.
Shenzhen VMAX New Energy (SHSE:688612)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Shenzhen VMAX New Energy Co., Ltd. focuses on the research, development, production, and sale of power electronics and power transmission products both in China and internationally, with a market cap of CN¥12.19 billion.
Operations: The company generates revenue of CN¥6.29 billion from its electric equipment segment.
Insider Ownership: 38.4%
Earnings Growth Forecast: 25.3% p.a.
Shenzhen VMAX New Energy is experiencing robust revenue growth, with sales reaching CNY 4.36 billion for the first nine months of 2024, up from CNY 3.59 billion a year earlier. Despite this, net income only slightly increased to CNY 296.13 million. The company's earnings are forecasted to grow significantly at 25.34% annually but below the market average in China. Its share buyback program aims to repurchase up to CNY 100 million worth of shares for equity incentives, reflecting strategic insider confidence without recent substantial insider trading activity.
- Take a closer look at Shenzhen VMAX New Energy's potential here in our earnings growth report.
- Our valuation report here indicates Shenzhen VMAX New Energy may be overvalued.
Sineng ElectricLtd (SZSE:300827)
Simply Wall St Growth Rating: ★★★★★★
Overview: Sineng Electric Co., Ltd. is involved in the research, development, manufacture, maintenance, and trading of power electronic products both in China and internationally, with a market cap of CN¥17.76 billion.
Operations: Sineng Electric Co., Ltd. generates revenue through its activities in the research, development, manufacturing, maintenance, and trading of power electronic products within China and on a global scale.
Insider Ownership: 36.3%
Earnings Growth Forecast: 39.7% p.a.
Sineng Electric Ltd. demonstrates strong growth potential, with earnings rising by 55.1% over the past year and expected to grow significantly at 39.7% annually, outpacing the Chinese market average. Despite a slight decline in revenue to CNY 3.07 billion for the first nine months of 2024, net income improved to CNY 301.87 million. The company is expanding into North America with its Power Conversion Systems for energy storage projects, enhancing its global footprint and technological offerings without recent insider trading activity noted.
- Get an in-depth perspective on Sineng ElectricLtd's performance by reading our analyst estimates report here.
- The analysis detailed in our Sineng ElectricLtd valuation report hints at an inflated share price compared to its estimated value.
Summing It All Up
- Take a closer look at our Fast Growing Companies With High Insider Ownership list of 1520 companies by clicking here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SHSE:688266
Suzhou Zelgen BiopharmaceuticalsLtd
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
Exceptional growth potential with excellent balance sheet.